1.	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer Phase: Phase IV Type: Supportive care, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CABAZ_L_06003, U1111-1123-9025, NCT01649635
2.	Treatment of Locally Advanced or Metastatic Transitional Cell Carcinoma With Cabazitaxel Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: RRK4368, 2012-002552-16, NCT01668459
3.	Cabazitaxel vs. Vinflunine in Metastatic or Locally Advanced Transitional Cell Carcinoma of the Urothelium (TCCU) Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: Secavin-12, NCT01830231
4.	Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CABAZ_C_05331, 2010-021128-92, U1111-1115-2476, NCT01254279
5.	Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: EFC11785, 2010-022163-35, NCT01308580
6.	Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer Phase: Phase III Type: Treatment Status: Active Age: Not specified Sponsor: Pharmaceutical / Industry Protocol IDs: OGX-011-12, NCT01578655
7.	Cabazitaxel With or Without Carboplatin in Patients With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Therapy Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2011-0727, NCT01505868
8.	Cabazitaxel in Patients With Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based Chemotherapy Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 11D.392, 2011-52, NCT01437488
9.	Phase II Study of Cabazitaxel-XRP6258 in Advanced Non-Small Cell Lung Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 19 and over Sponsor: Other Protocol IDs: F110512012 (UAB 1021), UAB 1021, NCT01438307
10.	Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel Phase: Phase II Type: Biomarker/Laboratory analysis, Supportive care, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: 4P-11-3, NCI-2011-03266, NCT01469338
11.	Cabazitaxel Compared to Topotecan for the Treatment of Small Cell Lung Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: ARD12166, 2011-003415-31, U1111-1123-3503, NCT01500720
12.	Study of Weekly Cabazitaxel for Advanced Prostate Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Other Protocol IDs: CABASEM-SOGUG, NCT01518283
13.	Study Comparing Two Treatments in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: UCL-ONCO 2011-01, 2011-001938-42, NCT01528163
14.	Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: MCC-16684, NCT01531205
15.	A Study Looking at Novel Scheduling of Cabazitaxel for Patients With Metastatic Prostate Cancer Phase: Phase II Type: Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 2011-004178-27, NCT01541007
16.	Second-line Chemotherapy in Castration Resistant Prostate Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2011-003156-39, NCT01558219
17.	Continued Treatment With Docetaxel Versus Switch to Cabazitaxel After Minor Prostate Specific Antigen Response to Docetaxel in Patients With Castration-Resistant Metastatic Prostate Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CABAZ_L_05933, U1111-1119-8381, NCT01576029
18.	A Trial of Cabazitaxel for Advanced Transitional Cell Carcinoma (TCC) Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: ISGUOG1101.CTIL, NCT01600339
19.	Bristol Bladder Trial Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: ON/2011/3775, 2011-004090-82, NCT01616875
20.	Cabazitaxel and Radiation For Patients With Pathologically Determined Stage 3 Prostate Cancer and/or Patients With PSA Elevation (>0.1- < 2.0 ng/mL) Phase: Phase II Type: Treatment Status: Active Age: Over 18 Sponsor: Other Protocol IDs: BrUOG 246, NCT01650285
21.	Study of Cabazitaxel in Patients With Metastatic Breast Cancer Previously Treated With Taxanes Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: HE 11B/11, 2011-003625-97, NCT01693549
22.	Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CABAZL06056, U1111-1130-9893, NCT01718353
23.	Cabazitaxel in Platinum Refractory Ovarian Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: TaxOvar, NCT01747239
24.	Cabazitaxel in Men 75 Years of Age or Older With Castration-Resistant Prostate Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Approved-not yet active Age: 75 and over Sponsor: Other Protocol IDs: CASE3811, NCI-2012-02993, NCT01750866
25.	Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 1208012946, NCT01757171